P46373 9th Annual Biomanufacturing
Download Brochure Request

Register your interest


Register your interest


9th Annual Biomanufacturing

14 – 16 May 2019, Shanghai Marriott Hotel Parkview, China

Book Now Download Brochure



The future of biomanufacturing is set for a revolution. New outsourcing trends, mass customisaton and precision medicine, intensification versus continuous models, and the rise of intelligent facilities, are but some of the issues driving the change. Smart biomanufacturing is increasingly playing a crucial role in fulfilling the needs of the market.

Further, as China’s MAH programme takes root, it is expected to give a major boost to the CMO market. IBC’s 9th Biomanufacturing Summit in China comes back as part of the BDP Week, comprising of 5 collocated events. It will justify your investment by offering debates, insights, learning seminars and networking with an unrivalled gathering of the biotech industry.

Discussion themes

  • Clinical and commercial phase market outlook for CMOs in China
  • Projecting impacts of the MAH programme
  • Capacity outlook – utilization rates, new investment and a medium term position
  • CMO pricing trends
  • Big Pharma insights on market segments driving new growth
  • Capitalising on the MaB therapeutics market
  • Smart Biomanufacturing – trends, investment and case studies
  • Automation and digitalisation trends
  • AI in Biomanufacturing – key components, and use cases
  • Case studies in Small scale, smart and flexible manufacturing systems and processes
  • Intelligent bio reactors, advantages, workings and benefits
  • Trends and best practice dominating Process intensification and Continuous manufacturing
  • Single use strategy and implementation
  • Staffing and skilling strategies
  • The latest in tech and equipment from top vendors, and how they are being implemented

Part of

5th Annual BioPharma Development and Production Week »

With demonstrated success year on year, IBCs BDP Week in China enjoys unparalleled industry support. Known for generating knowledge, creating business opportunities, and bringing innovative ideas to the table, the BDP Week is now more impactful than ever with 5 high level conferences, learning seminars, focused trade show and business matching to boot.

Co located conferences

The BDP Party!

When: Wednesday, 15 May 2019 at 6.30pm
Where: Shanghai City Bistro, Level 1, Shanghai Marriott Parkview Hotel
Cost: CNY 350 / USD 50 net (inclusive of buffet dinner and free flow wine / beer)

  • Registration is not limited to conference participants and we encourage all who are in the BDP industry to attend.
  • Dinner will only proceed when we have reached 100 participants.
  • Payment is only required when the dinner is confirmed.
  • Participants list for the dinner will be made available online once the registration reaches 100 participants.


8:00 am

Main Conference Registration and Morning Coffee

9:00 am

Chairperson’s Opening Remarks


9:05 am

Outlook for China’s BDP Market – Investments, Regulations, Innovation and Vision of Chinese Manufacturers

Senior Representative from Fosun Pharma*,

10:30 am

Morning Networking and Refreshment Break


11:20 am

Chairperson’s Opening Remarks

Dr Junli Zhang, Senior Vice President of Global Manufacturing and Technical Operation, Shanghai Henlius Biotech, Inc.


11:30 am

  • Evaluating new tech platforms for commercial manufacturing
  • Where do we see the shift in digitalisation in China?
  • Tech transfer, single-use, and manufacturing process control
  • A case study of open-access technology platform

12:00 pm

Promoting Scalability by Bioprocessing in a Flexible, Open, and Agile Automation Platform

Jason Lukasek, Senior Director, BEA, BPD Commercial, Thermo Fisher Scientific

12:30 pm

Networking Lunch

1:30 pm

  • Key points on digital transformation – Embracing the change in process, technology and human resource
  • Meeting the demand of global pharmaceutical market and China’s role in speed-to-market
  • The emergence of CDMOs and their tech capabilities in China
  • Evaluating digital strategy in China and building smart facilities
  • Digital transformation in vaccines, mAbs, and biologics manufacturing
  • Automation and digitalisation trends


2:10 pm

Effect of Fully Continuous Process for Mab Manufacturing: Speed to Market and Cost Reduction (TBC)

Senior Representative from PALL,

2:40 pm

  • The trend in biologics development and manufacturing needs
  • Update on disposable continuous manufacturing GMP facilities
  • Implementation case study of an antibody continuous processing manufacturing facility
  • Facility investment trends

3:10 pm

Afternoon Networking & Refreshment Break

3:40 pm

  • Working with NMPA’s requirement on MGP standards and manufacturing compliance
  • EU requirement – Facility design and manufacturing processes
  • One-off production technology in both upstream and downstream for biosimilars
  • How Henlius is adopting facility of future and latest technologies?


5:00 pm

Chairperson’s Summary and End of Main Conference Day One

8:55 am

Chairperson’s Opening Remarks


9:10 am

  • Working with QC and QA oversight and operations, Quality Systems, regulatory guidelines and requirements
  • CMC development from pre-clinical to market filing
  • Working with CROs and CMOs to achieve quality products
  • Case study of CMC development of biologics from preclinical to commercial launch and post-commercial support

9:40 am

Internationalisation of Local Manufactured Drugs through Quality and Manufacturing Excellence

Michelle Peake, Senior General Manager, PT Kalbio Global Medika, Indonesia

10:20 am

Morning Networking and Refreshment Break

11:00 am

  • How QbD is changing the landscape of biopharma manufacturing?
  • Managing manufacturing risk assessment, process analytical technology (PAT) implementation of large scale continuous manufacturing
  • Managing manufacturing costs
  • Meeting GMP standards and manufacturing excellence


11:30 am

  • Minimizing initial investment and time to the clinic – early phase product strategy
  • Establishing a commercially viable process up front avoid costly rework and delay
  • Ensuring continuous supply in both clinical and commercial lifecycle
  • Approaching process development program and streamlined tech transfer

12:00 pm

  • Feasibility analysis on single-use facilities
  • How to implement single-use solution to optimize up-streaming processing
  • Advantages and feasibility of single-use solutions in down-streaming separation and purification

12:30 pm

Networking Lunch

1:30 pm

  • Big Pharma insights on market segments driving new growth and needed manufacturing capacity
  • Evaluating modular facility for manufacturing in China
  • Design and tech investments
  • Case study

2:00 pm

  • Addressing key components, and use cases
  • AI in Biomanufacturing – key components, and use cases
  • How do we instill intelligent bio reactors, advantages, workings and benefits?
  • Perspectives on technology that streamlining operation to be more effective and present higher yield


2:30 pm

Advances in Magnetic Bead Antibody Purification

John K. Kawooya, Director, Biologics Optimization, Amgen, Inc.

3:00 pm

  • Operations for an autologous cell therapy
  • Case study for scaling up
  • Challenges in utilising different cell types such as bi-specific CAR-T cells, regulatory T cells and hematopoietic stem cells
  • Implementing automated solutions across the cell and gene therapy manufacturing pathway.
  • Key processing challenges for cell and gene therapy products

3:30 pm

Afternoon Networking & Refreshment Break


5:00 pm

Chairperson’s Summary and End of the Conference

9:00 am

China’s biopharma industry continues to grow rapidly  and hails as a major investment region in the world. With tides of tech innovation, market growth in CRO, CMO and CDMO, a numerous clinical trials projects lined-up, newly discovered therapies to the market and upgrading manufacturing facilities to name a few. This workshop aims to provide a strategic snapshot of the investment landscape for biopharma medicine, and covers practical aspects on how biotech companies can navigate the investment and pricing options for related drugs and treatments to generate better returns.

You will learn:

  • Financing clinical trials operations
  • R&D investment and financing models
  • Manufacturing financing
  • Financial partnership with Chinese pharma and biotech
  • Biosimilars products financing
  • Going Public and Listing insights
  • Deal, debt and equity structuring

1:00 pm

End of Workshop


Packages Price
2 Day Conference - International Companies, Global HQ Located Outside ChinaUS $1895Early Bird
Group of 2 or more delegates - International Companies, Global HQ Located Outside ChinaUS $1495Early Bird
Group of 4 or more delegates - International Companies, Global HQ Located Outside ChinaUS $1295Early Bird
2 Day Conference - Local China CompaniesUS $977Early Bird
Group of 2 or more delegates - Local China CompaniesUS $752Early Bird
Group of 4 or more delegates - Local China CompaniesUS $676Early Bird
Gala Dinner (For Non Delegates)US $50Early Bird
Extras Price
Pre Conference Workshop - International Companies, Global HQ Located Outside China US $300
Pre Conference Workshop - Local China Companies US $150
Gala Dinner US $50

Early Bird Rate: Register & Pay by 8 March 2019

  • Multiple Bookings Discount pricing is applicable to groups of 2 or more delegates from the same organisation registering for the same event, at the same time.
  • Fee stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR group rate.
  • All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.
  • All delegates from Singapore-based companies are required to pay an additional 7% GST (SINGAPORE EVENTS ONLY)
  • View payment terms and bank transfer details, click here »

CNY Pricing

  • 2 Day Conference: CNY 6,500
  • Group of 2 or more delegates: CNY 5,000
  • Group of 4 or more delegates: CNY 4,500
  • Pre Conference Workshop: CNY 1,000
  • Gala Dinner: CNY 350


Partnership and Profile Building Opportunities are Now Available!
Contact us today to find out how you can position your company as a market leader at this event, and to explore the range of branding and marketing opportunities available.


Senior Representative from Fosun Pharma*

Richard Wang

CEO, Fosun Kite Biotech, China

He Ting

Chief Executive Officer, ImmunoChina, China

Dong Wei

CEO, Edigene, China

Zonghai Li

President and Chief Executive Officer, CARsgen Therapeutics, China

Peter Luo

CEO, Adagene Pharma, China

Ruirong Yuan

President, Chief Medical Officer and Board Director, Adlai Nortye Biopharma, China

Eddy Wu

China Head/Vice-President, Terns Pharmaceutical, China

Jonathan Zhao 4th Annual Bioprocess and Technology 2018

Jonathan Zhao

PhD, Co-founder and Chief Executive Officer, Hangzhou JUST Biotherapeutics, China

Zhou Mingdong

CEO and Chief Scientist, Zensun, China

Zhengyu Yuan

President & Chief Executive Officer, MicuRx Pharmaceuticals Inc., China

Dr Junli Zhang

Senior Vice President of Global Manufacturing and Technical Operation, Shanghai Henlius Biotech, Inc.

Jian Dong

Senior Vice President Global Biomanufacturing and & Wuxi Site Head of Manufacturing, Wuxi Biologics, China

Jason Lukasek

Senior Director, BEA, BPD Commercial, Thermo Fisher Scientific

Dr. Xiangyang Zhu

Chief Executive Officer, Huabo Biopharma, China

Racho Jordanov

Co-founder, Co-Chairman, President and Chief Executive Officer, JHL Biotech, China

Jerry Yang

Senior Vice President, Process & Product Development, Hangzhou JUST Biotherapeutics Co., Ltd. China

Senior Representative from PALL

Dr. Qinghai Zhao

Vice President, Technical Development and Manufacturing, Forty-Seven Inc. USA

Xu Wei

Vice President, Manufacturing, Innovent Biologics, China

Wenzhi Tian

MD, Chairman & CEO, ImmuneOnco Biopharma Co., Ltd, China

Michelle Peake

Senior General Manager, PT Kalbio Global Medika, Indonesia

Dr Jerry Dong

Vice President of CMC and Regulatory Affairs, Shanghai Henlius Biotech, Inc.

Dr Wu Youling

Chief Executive Officer, ZheJiang Teruisi Biopharmaceutical, China

Rhona McIntyre

Associate Director Commercial Development, Lonza Pharma & Biotech

Shou Bai Chao

Senior Vice President, Bio Venture AstraZeneca China

John K. Kawooya

Director, Biologics Optimization, Amgen, Inc.

Dr. Lin Yang

Chief Executive Officer, PersonGen Biomedicine, China

Dr. Alvin Luk

Senior Vice President and Chief Medical Officer, Shanghai Henlius Biotech, Inc., China

Chen-Yuan Lin

Ward Director and Attending Physician at the Division of Hematology and Oncology, China Medical University Hospital, Taiwan

Dr Lin Shiwen

Vice President of Downstream Process Development, WuXi Biologics, China

Dr. Senyon Choe (Teddy)

Professor, Biology, University of California San Diego (UCSD), U.S. and President and Director of Joint Center for Biosciences, South Korea

Xiaodi Su

Senior Investment Manager, Lilly Asia Ventures, China

Jieyu Zou

Vice President, Lilly Asia Ventures, China

when & where

14 - 16 May 2019

Shanghai Marriott Hotel Parkview
333 Guang Zhong Road West, Jing’an District
Shanghai, 200072 China
Phone:+86 21 3669 8888
Fax:+86 21 3669 8668

Cartrina Wang 王洁琼 | Senior Sales Manager-EBC
T: 86 21 3669 8666 | M:13585605981



Still have a question?

Speaking Opportunities
Sophia Zhao
+65-6508 2491

Sponsorship Opportunities
Yvonne Leong
+65 6508 2489


Media & Association Partnership Opportunities
Tham Ruohyi
+65 6508 2463





Conference Partner Conference Partner


IBC Asia is Singapore's leading event organiser. We conceive, develop and promote our own B2B industry conferences and corporate training courses, and offer tailored managed event solutions.

Find out more